EBR Systems
- Company typePublic
- Founded2003
- HeadquartersSunnyvale, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
EBR Systems firmographics
Firmographics- Name
- EBR Systems
- Legal name
- EBR Systems, Inc.
- Website
- https://ebrsystemsinc.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
EBR Systems industry classification
Industry- Product category
- Cardiac Resynchronization Therapy Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cardiac Rhythm Management (Pacemakers, ICDs, CRT) (HLAHAFAC)
- akta.pro secondary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
Keywords
Where EBR Systems is headquartered
LocationHeadquarters
- HQ city
- Sunnyvale
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
EBR Systems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- WiSE CRT System Device Sales: EBR Systems generates revenue from the sale of its WiSE CRT System hardware, including the electrode, transmitter, battery, coupler, programmer, and delivery sheath. The company reported initial commercial revenue of $1.6 million in 2025 following FDA approval and U.S. commercial launch. The target average selling price (ASP) for the system is US$45,000.
- CMS Reimbursement (NTAP and TPT): CMS provides New Technology Add-On Payment (NTAP) of up to $41,145 per procedure for inpatient use, on top of base DRG reimbursement. Transitional Pass-Through (TPT) reimbursement supports outpatient settings, both effective October 1, 2025. Additionally, CMS has initiated a National Coverage Determination (NCD) for the WiSE wireless LV pacing system, with a projected decision in early 2027. EBR is also the first technology to enter CMS' Transitional Coverage for Emerging Technologies (TCET) pathway.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | WiSE CRT System target average selling price (ASP) |
| Transaction based/ take rate | Pay-as-you-go | CMS NTAP (New Technology Add-On Payment) for inpatients |
| Transaction based/ take rate | Pay-as-you-go | CMS TPT (Transitional Pass-Through) for outpatients |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
EBR Systems product offering
Product offeringCore offering
EBR Systems develops, manufactures, and commercializes the WiSE (Wireless Stimulation Endocardially) System, the first FDA-approved wireless cardiac pacing system for heart failure patients. The system delivers leadless left ventricular endocardial pacing (LVEP) for cardiac resynchronization therapy (CRT) through a rice-grain-sized electrode powered by subcutaneous ultrasound, sold to hospitals and electrophysiologists at a target average selling price of US$45,000 per system.
Product overview
EBR Systems offers the WiSE System, a single unified product platform for wireless cardiac resynchronization therapy. The system consists of the WiSE Electrode (a leadless left ventricular endocardial pacing device), Battery Module, Transmitter, Programmer, Delivery Sheath, and Coupler components that work together to deliver leadless biventricular pacing for heart failure patients. The WiSE System is the world's only FDA-approved wireless cardiac pacing device, using proprietary ultrasound technology to pace the left ventricle without requiring transvenous leads. The system is designed to work with patients' existing co-implanted pacemakers, ICDs, or CRT devices to provide synchronized cardiac resynchronization therapy.
Differentiator
Problem solved
Functional benefit
Products and services
- WiSE System (Wireless Stimulation Endocardially) The WiSE System is the world's only FDA-approved wireless cardiac pacing device for heart failure, delivering leadless left ventricular endocardial pacing (LVEP) for cardiac resynchronization therapy. It uses proprietary ultrasound technology to pace the left ventricle without transvenous leads.
Quantifiable outcome
- 16.4% improvement in left ventricular end systolic volume (LVESV) in heart failure patients in the first 6 months post-implant
- +7 more outcomes
Companies that use EBR Systems
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
EBR Systems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
EBR Systems partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major and minor.
- HCA HealthcaremajorMajor US healthcare network that has entered into a purchasing agreement with EBR Systems for the WiSE System. HCA Healthcare is one of the largest hospital operators in the US, with significant cardiac care capabilities.
- Advocate HealthmajorMajor US healthcare network that has entered into a purchasing agreement with EBR Systems for the WiSE System. Advocate Health is one of the largest healthcare systems in the US.
- CHRISTUS HealthmajorMajor US healthcare network that has entered into a purchasing agreement with EBR Systems for the WiSE System. CHRISTUS Health operates hospitals and healthcare services across the US and Latin America.
- Telectronics Legacy ConnectionminorTrevor Moody, a former Telectronics biomedical engineer, connected EBR to Australian investors. Telectronics was Australia's first successful high-tech medical electronics company (founded in Sydney in 1963), manufacturing pacemakers and implantable defibrillators. This connection explains EBR's ASX listing and Australian investor base, as Telectronics pioneered pacemaker technology in Australia.
Scale indicators15 records
Recent moves8 records
Expansion highlights6 records
EBR Systems competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Global leader in cardiac rhythm management including conventional CRT-D systems and the Micra leadless pacemaker. Competes indirectly with WiSE in serving heart failure patients but dominates the broader CRT market that EBR's WiSE system augments rather than displaces.
- Abbott: Major manufacturer of conventional CRT systems and leadless pacemakers (Nanostim lineage). Competes in the same cardiac rhythm management space and represents both a co-implant compatibility partner and a potential future competitor in leadless LVEP.
- Boston Scientific: Major incumbent in cardiac rhythm management with conventional CRT systems and a growing leadless pacemaker portfolio. Competes in the same hospital accounts and EP physician relationships that EBR is now selling into.
Direct peers
- CVRx: Developer of the Barostim implantable neuromodulation system for heart failure patients — a competing implantable device approach for the same advanced heart failure population EBR targets with WiSE, making it the most analogous direct peer in terms of patient indication and use setting.
- Biotronik: European-based cardiac rhythm management company with CRT and leadless pacemaker products. Closest direct comparable as a smaller, technology-focused CRT specialist competing in the same electrophysiology hospital accounts.
Emerging players
- LivaNova: Cardiac device company with heart failure and cardiac rhythm management products. Competes in adjacent cardiac device categories and shares the same specialty hospital accounts targeted by EBR.
- Axonics: Implantable neuromodulation company (sacral and now tibial stimulation) that shares the miniaturized implantable technology paradigm with EBR's WiSE electrode. Both pursue leadless or minimally-invasive implantable approaches with rechargeable/ultrasound energy concepts.
- Acutus Medical: Cardiac electrophysiology mapping and ablation company with similar small-cap medtech profile to EBR. Operates in the same EP lab and electrophysiologist customer base that EBR's WiSE System depends on for adoption.
Regional players
- MicroPort Scientific: China-based medical device company with a cardiac rhythm management business including CRT products. Comparable technology category but primarily serves the Asia-Pacific market where EBR has limited presence outside Australia.
Others
- SetPoint Medical: Implantable neuromodulation company chaired by Allan Will (EBR's Executive Chairman). Shares a leadership connection and pursues a similar minimally-invasive implantable device paradigm, making it a thematically related peer rather than a direct competitor.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
EBR Systems social profiles
Digital presenceEBR Systems compliance and trust
Trust signalCompliance1 record
EBR Systems financial estimates
Financial estimateRevenue estimate
Valuation estimate
EBR Systems leadership team
Management profileNumber of profiles
Profiles16 records
EBR Systems funding detail
Funding detailFunding overview
Funding rounds11 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EBR Systems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EBR Systems
What does EBR Systems do?
EBR Systems develops, manufactures, and commercializes the WiSE (Wireless Stimulation Endocardially) System, the first FDA-approved wireless cardiac pacing system for heart failure patients. The system delivers leadless left ventricular endocardial pacing (LVEP) for cardiac resynchronization therapy (CRT) through a rice-grain-sized electrode powered by subcutaneous ultrasound, sold to hospitals and electrophysiologists at a target average selling price of US$45,000 per system.
Is EBR Systems a public or private company?
EBR Systems is a public company. It is classified as public and is currently operating.
When was EBR Systems founded?
EBR Systems was founded in 2003. It employs 51 to 100 people.
Where is EBR Systems based?
EBR Systems is headquartered in Sunnyvale, United States, in the North America region.
How does EBR Systems make money?
Two revenue lines are on record. WiSE CRT System Device Sales are the primary driver. The others are CMS Reimbursement (NTAP and TPT).
Who are EBR Systems's main competitors?
Broad incumbents on record are Medtronic, Abbott and Boston Scientific. Direct peers are CVRx and Biotronik. Emerging players are LivaNova, Axonics and Acutus Medical. MicroPort Scientific is listed as a regional player. SetPoint Medical is listed as an others.
Does EBR Systems have an API?
No public API is recorded for EBR Systems.
What industry is EBR Systems in?
EBR Systems's product category is Cardiac Resynchronization Therapy Devices. Its primary akta.pro industry code is HLAHAFAC, Cardiac Rhythm Management (Pacemakers, ICDs, CRT), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.